• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

广告
第一作者: Iris,Nederlof
第一单位: Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
作者单位: Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [1] Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Oncode Institute, Utrecht, the Netherlands. [2] Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, Leuven, Belgium. [3] Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [4] Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [5] Department of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.;Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [6] Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [7] Department of Pathology, OLVG Hospital, Amsterdam, the Netherlands. [8] Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [9] Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [10] Medical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands. [11] Department of Oncology, OLVG Hospital, Amsterdam, the Netherlands. [12] Natera, San Carlos, CA, USA. [13] Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [14] Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [15] Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Oncode Institute, Utrecht, the Netherlands.;Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands. [16] Department of Pathology, ZAS hospitals, Antwerp, Belgium.;Division of Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. [17] Oncode Institute, Utrecht, the Netherlands.;Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [18] Oncode Institute, Utrecht, the Netherlands.;Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.;Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands. [19] Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.;Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl. [20]
DOI 10.1038/s41591-024-03249-3
PMID 39284953
发布时间 2024-12-05
提交
  • 浏览0
Nature medicine

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷